
Topic
Drug Pricing
WAC, ASP, NADAC, IRA negotiated prices, inflation rebates, and drug cost trends affecting access and coverage.

Approvals· June 10, 2026 · 10 min read
By Ran Chen#FDA Approval#Generic Entry#Biosimilars

Policy· June 10, 2026 · 9 min read
What's in short supply: 1,146 shortages, two-thirds injectable, and an anesthesia crisis
By Ran Chen#Supply Chain#FDA Approval#Drug Pricing

Approvals· June 10, 2026 · 10 min read
What the EU approves: 2,313 medicines, 29% oncology, 28 biosimilars in 2024

Manufacturing· June 10, 2026 · 9 min read
Who supplies the world's essential medicines: 1,139 WHO-PQ products, 59% from India

Pricing & Access· June 9, 2026 · 10 min read
Awiqli coverage guide: insulin icodec access, PA criteria, and Part D pricing

Generics· June 9, 2026 · 9 min read
Dapagliflozin generic entry: Farxiga ANDA playbook and formulary impact
By Ran Chen#SGLT2 Inhibitor#ANDA Approval#Orange Book

Policy· June 9, 2026 · 12 min read
IRA Medicare drug negotiation third cycle: 15 drugs selected for 2028

Pricing & Access· June 1, 2026 · 12 min read
IRA Part B drug negotiation: provider reimbursement risk under the buy-and-bill model

Pricing & Access· May 31, 2026 · 12 min read
Medicare Part D $2,100 out-of-pocket cap and hub impact in 2026

Pricing & Access· May 31, 2026 · 11 min read